What is William Blair's Estimate for Harrow FY2025 Earnings?

Key Points

• William Blair has increased its FY2025 earnings per share estimate for Harrow, Inc. to $0.37, up from $0.33, while maintaining an "Outperform" rating on the stock.
• Harrow reported $0.24 earnings per share for its latest quarter, exceeding the consensus estimate of $0.01 by $0.23, with revenues of $63.74 million.
• Institutional investors, including Voya Investment Management and Bank of America, have significantly increased their stakes in Harrow, which now has a strong holding of 72.76% by such investors.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Investment analysts at William Blair upped their FY2025 earnings per share estimates for shares of Harrow in a research report issued on Monday, September 29th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of $0.37 for the year, up from their previous estimate of $0.33. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's Q4 2025 earnings at $0.40 EPS, Q2 2026 earnings at $0.47 EPS, Q3 2026 earnings at $0.44 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $1.52 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The business had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

HROW has been the topic of several other reports. Cantor Fitzgerald began coverage on Harrow in a research report on Friday, July 11th. They issued an "overweight" rating and a $76.00 target price on the stock. BTIG Research restated a "buy" rating and issued a $63.00 target price on shares of Harrow in a research report on Wednesday, September 24th. Zacks Research cut Harrow from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 12th. Lake Street Capital raised their target price on Harrow from $42.00 to $70.00 and gave the company a "buy" rating in a research report on Monday. Finally, Craig Hallum lifted their price target on Harrow from $54.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, September 23rd. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Harrow currently has an average rating of "Moderate Buy" and a consensus price target of $67.83.

Harrow Stock Up 2.8%

HROW opened at $48.40 on Tuesday. Harrow has a 12 month low of $20.85 and a 12 month high of $59.23. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The stock has a market cap of $1.79 billion, a P/E ratio of -193.60 and a beta of 0.33. The stock's 50 day moving average price is $38.70 and its 200 day moving average price is $31.68.

Hedge Funds Weigh In On Harrow

Several hedge funds have recently modified their holdings of the company. Voya Investment Management LLC boosted its stake in shares of Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock worth $10,147,000 after acquiring an additional 372,237 shares in the last quarter. Diametric Capital LP bought a new stake in shares of Harrow during the 2nd quarter worth $4,748,000. Bank of America Corp DE boosted its stake in shares of Harrow by 266.8% during the 2nd quarter. Bank of America Corp DE now owns 213,448 shares of the company's stock worth $6,519,000 after acquiring an additional 155,258 shares in the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of Harrow during the 2nd quarter worth $4,293,000. Finally, Invesco Ltd. boosted its stake in shares of Harrow by 967.6% during the 2nd quarter. Invesco Ltd. now owns 150,948 shares of the company's stock worth $4,610,000 after acquiring an additional 136,809 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.